Transcatheter Heart Valve Replacement Market, Size, Global Forecast 2023-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis

Transcatheter Heart Valve Market is estimated to be US$ 15.14 Billion in 2030

Global Transcatheter Heart Valve Market is estimated to be US$ 15.14 Billion in 2030, according to the publisher. Over the past decade, the number of bio-prosthetic valve implants has steadily increased, leading to a growing population of patients who may require reoperation due to valve deterioration. In response, valve-in-valve transcatheter aortic valve replacement has emerged as a safe and effective alternative to surgery, specifically approved for higher-risk, inoperable patients. This complex procedure requires skilled personnel and should be performed in specialized centers to mitigate the higher risk of peri- and post-procedural complications compared to TAVR on native valves.

Aortic stenosis, a condition where the aortic valve doesn't fully open, restricts blood flow and necessitates treatment such as transcatheter aortic valve implantation. The rising prevalence of aortic stenosis, coupled with improved surgical techniques and growing demand for surgical technologies, is driving the transcatheter aortic valve replacement (TAVR) market. Increased healthcare investments, globally, are further supporting the market's expansion. Additionally, factors such as the growing acceptance rate of TAVI treatments, new device approvals, and a wealth of clinical evidence on their success are propelling market demand.

Global transcatheter aortic valve replacement (TAVR) market is projected to experience a strong compound annual growth rate (CAGR) of 12.73% from 2022 to 2030

The global transcatheter heart valve replacement market is witnessing significant growth due to the rise in the prevalence of valvular heart diseases and the increasing demand for minimally invasive procedures. The aging population, particularly those affected by heart valve diseases, is driving the need for valve replacement surgeries. Advancements in surgical techniques are further contributing to the growth of the transcatheter heart valve replacement market. Favorable reimbursement policies and the growing interest of manufacturers are also boosting market revenue.

However, strict regulations for the approval of transcatheter aortic valves and the high cost of TAVI procedures pose challenges to market expansion. Nevertheless, the use of TAVI systems for new indications, increased healthcare spending in emerging economies, and the involvement of key players in the global TAVI industry are expected to create growth opportunities throughout the forecast period. The global transcatheter aortic valve implantation market was valued at US$ 5.81 Billion in 2022.

Market share of TAVR is expected to continue its upward trajectory in the global healthcare landscape

By Type, Transcatheter Heart Valve Replacement Market is divided into TAVR, TMVR and TPVR. Transcatheter Aortic Valve Replacement (TAVR) has emerged as a leading procedure in the global medical market, capturing the highest market share. The increasing prevalence of cardiovascular diseases, particularly aortic valve disorders, has contributed to the rising demand for TAVR procedures. This minimally invasive technique offers numerous benefits, including reduced hospital stay, faster recovery time, and improved patient outcomes.

Moreover, advancements in TAVR device technologies, coupled with the growing acceptance of this procedure among healthcare professionals, have further fueled its market dominance. With ongoing research and development efforts and a favorable reimbursement landscape, the TAVR market is projected to maintain its significant market share in the foreseeable future.

Biological tissue market segment is experiencing rapid growth within the Transcatheter Aortic Valve Replacement (TAVR) industry

By Material, Transcatheter Heart Valve Replacement Market is segmented into Mechanical valves and Biological tissue. The biological tissue market within the Transcatheter Aortic Valve Replacement (TAVR) industry is experiencing rapid growth and emerging as the fastest-growing segment. Biological tissue valves, also known as bioprosthetic valves, offer advantages such as improved durability and reduced risk of blood clots compared to mechanical valves. This has led to increased adoption of biological tissue valves in TAVR procedures, especially among elderly patients who require valve replacement. The market growth is further fueled by advancements in tissue engineering, which have led to the development of more durable and long-lasting biological tissue valves. With ongoing research and technological innovations, the biological tissue market is poised to continue its upward trajectory within the TAVR industry.

Growing prominence of ASCs is expected to reshape the landscape of TAVR and drive its rapid expansion in the coming years

By End User, Transcatheter Heart Valve Replacement Market is classified into Hospital, Ambulatory surgical centers and others. The ambulatory surgical centers (ASCs) segment is emerging as the fastest growing sector within the Transcatheter Aortic Valve Replacement (TAVR) industry. ASCs provide a convenient and cost-effective alternative to traditional hospital settings for performing TAVR procedures.

With advancements in medical technology and improved patient outcomes, more TAVR procedures can now be safely conducted in outpatient settings. ASCs offer shorter hospital stays, reduced healthcare costs, and greater accessibility for patients. Additionally, ASCs focus on delivering specialized care and personalized patient experiences, attracting more physicians and patients to choose these centers for TAVR procedures.

Transcatheter Aortic Valve Replacement (TAVR) industry in India is rapidly evolving and witnessing significant growth

By Countries, Transcatheter Heart Valve Replacement Market is breakup into US, Canada, Mexico, Brazil, Argentina, Germany, Spain, United Kingdom, Italy, France, Indonesia, Malaysia, India, Thailand, Japan, China, South Korea, Australia, New Zealand, South Africa, Saudi Arabia, UAE, Turkey and Rest of the world. The United States Transcatheter Aortic Valve Replacement (TAVR) industry is experiencing significant growth and innovation. With a rising prevalence of aortic valve diseases and an aging population, TAVR has emerged as a preferred alternative to traditional open-heart surgery.

The market is driven by advanced medical technologies, a robust healthcare infrastructure, and a favorable reimbursement landscape. Major medical device companies, research institutions, and healthcare providers are actively engaged in expanding TAVR procedures and improving patient outcomes. Continuous advancements in device design, minimally invasive techniques, and clinical research are propelling the growth of the United States TAVR industry, positioning it as a global leader in this life-saving procedure.

With a large population and increasing prevalence of aortic valve diseases, there is a growing need for advanced treatment options like TAVR. The market is characterized by a rising number of medical institutions offering TAVR procedures, advancements in healthcare infrastructure, and increased awareness among healthcare professionals and patients. Government initiatives and favorable reimbursement policies are further fueling the growth of the TAVR industry in India. With continuous advancements in technology, increasing collaborations with international medical device companies, and ongoing research and development efforts, the Indian TAVR industry is poised for significant expansion and plays a vital role in improving cardiac care in the country.

Key Company

In the Valve Replacement (TAVR) industry, several key players have emerged as industry leaders. Edwards Life Sciences, Abbott Laboratories, Medtronic Plc, LIVANOVA PLC, Boston Scientific Corporation, Artivion, Inc, MicroPort Scientific Corporation, and Venus Medtech (Hangzhou) Inc are among the prominent companies driving innovation and advancements in this field.

This latest report ""Transcatheter Heart Valve Replacement Market Global Forecast by Type (Transcatheter Aortic Valve Replacement Market, Transcatheter Mitral Valve Replacement Market and Transcatheter Pulmonary Valve Replacement Market), Material (Mechanical Valve, Biological Valve), Country (US, Canada, Mexico, Brazil, Argentina, Germany, Spain, United Kingdom, Italy, France, Indonesia, Malaysia, India, Thailand, Japan, China, South Korea, Australia, New Zealand, South Africa, Saudi Arabia, UAE, Turkey and Rest of the world), End-Users (Hospitals,Ambulatory surgical centres, others), Company (Edwards Life sciences, Abbott Laboratories, Medtronic Plc, LIVANOVA PLC, Boston Scientific Corporation, Artivion, Inc, MicroPort Scientific Corporation and Venus Medtech (Hangzhou) Inc.)” provides a detailed analysis of Global Transcatheter Heart Valve Replacement Industry.

Transcatheter Heart Valve Replacement Market by Type has been covered from 3 viewpoints

1. Transcatheter Aortic Valve Replacement
2. Transcatheter Mitral Valve Replacement
3. Transcatheter Pulmonary Valve Replacement

Transcatheter Aortic Valve Replacement Market has been covered from 2 viewpoints

1. Mechanical Valve
2. Biological Valve

Transcatheter Mitral Valve Replacement Market has been covered from 2 viewpoints

1. Mechanical Valve
2. Biological Valve

Transcatheter Pulmonary Valve Replacement Market has been covered from 2 viewpoints

1. Mechanical Valve
2. Biological Valve

By Country - Transcatheter Heart Valve Replacement Market

1. North America

1.1 United States
1.2 Canada

2. Latin America

2.1 Mexico
2.2 Brazil
2.3 Argentina

3. Europe

3.1 Germany
3.2 Spain
3.3 United Kingdom
3.4 Italy
3.5 France
3.6 Turkey

4. Asia Pacific

4.1 Indonesia
4.2 Malaysia
4.3 India
4.4 Thailand
4.5 Japan
4.6 China
4.7 South Korea
4.8 Australia
4.9 New Zealand

5. Middle East & Africa

5.1 South Africa
5.2 Saudi Arabia
5.3 UAE

6. Rest of the World

Transcatheter Heart Valve Replacement Market by End-User has been covered from 3 viewpoints

1. Hospital
2. Ambulatory surgical centers
3. Others

Company Insights

• Overviews
• Recent Developments
• Revenues

Company:

1. Edwards Life sciences
2. Abbott Laboratories
3. Medtronic Plc
4. LIVANOVA PLC
5. Boston Scientific Corporation
6. Artivion, Inc,
7. MicroPort Scientific Corporation
8. Venus Medtech (Hangzhou) Inc.